Toshimi Takano

8.0k total citations · 1 hit paper
172 papers, 3.0k citations indexed

About

Toshimi Takano is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Toshimi Takano has authored 172 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Oncology, 86 papers in Pulmonary and Respiratory Medicine and 49 papers in Cancer Research. Recurrent topics in Toshimi Takano's work include HER2/EGFR in Cancer Research (56 papers), Cancer Treatment and Pharmacology (45 papers) and Advanced Breast Cancer Therapies (33 papers). Toshimi Takano is often cited by papers focused on HER2/EGFR in Cancer Research (56 papers), Cancer Treatment and Pharmacology (45 papers) and Advanced Breast Cancer Therapies (33 papers). Toshimi Takano collaborates with scholars based in Japan, United States and Spain. Toshimi Takano's co-authors include Yuichiro Ohe, Koji Tsuta, Ikuo Sekine, Hideo Kunitoh, Tomohide Tamura, Noboru Yamamoto, Hiroshi Nokihara, Seiichiro Yamamoto, Yoshihiro Matsuno and Hiromi Sakamoto and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Cell.

In The Last Decade

Toshimi Takano

163 papers receiving 2.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer

2005 606 citations Toshimi Takano, Yuichiro Ohe et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Toshimi Takano Japan	25	2.1k	1.7k	628	616	256	172	3.0k
Koichi Minato Japan	29	2.1k 1.0×	1.6k 0.9×	781 1.2×	364 0.6×	140 0.5×	171	3.1k
Conor Steuer United States	27	1.4k 0.7×	1.4k 0.8×	797 1.3×	512 0.8×	234 0.9×	121	2.8k
Thomas Brodowicz Austria	28	2.4k 1.1×	2.0k 1.2×	585 0.9×	468 0.8×	350 1.4×	126	3.4k
R. Delva France	21	1.3k 0.6×	1.3k 0.8×	657 1.0×	538 0.9×	218 0.9×	99	2.5k
G. Deplanque France	23	1.3k 0.6×	812 0.5×	633 1.0×	542 0.9×	221 0.9×	77	2.3k
Motoki Yano Japan	34	1.2k 0.6×	2.0k 1.2×	1.1k 1.8×	538 0.9×	209 0.8×	170	3.7k
Hervé Curé France	20	1.3k 0.6×	827 0.5×	279 0.4×	510 0.8×	297 1.2×	52	2.3k
Michele Aieta Italy	24	1.2k 0.6×	997 0.6×	638 1.0×	600 1.0×	166 0.6×	116	2.3k
Simon Thézenas France	29	1.7k 0.8×	786 0.5×	830 1.3×	723 1.2×	363 1.4×	117	3.0k
Young Hak Kim Japan	30	1.9k 0.9×	1.7k 1.0×	644 1.0×	279 0.5×	109 0.4×	127	2.8k

Countries citing papers authored by Toshimi Takano

Since Specialization

Citations

This map shows the geographic impact of Toshimi Takano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshimi Takano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshimi Takano more than expected).

Fields of papers citing papers by Toshimi Takano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshimi Takano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshimi Takano. The network helps show where Toshimi Takano may publish in the future.

Co-authorship network of co-authors of Toshimi Takano

This figure shows the co-authorship network connecting the top 25 collaborators of Toshimi Takano. A scholar is included among the top collaborators of Toshimi Takano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshimi Takano. Toshimi Takano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fehm, Tanja, Francesco Cottone, Fabrice André, et al.. (2024). Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. The Lancet Oncology. 25(5). 614–625. 16 indexed citations

Takano, Toshimi, Norikazu Masuda, Mitsuya Ito, et al.. (2024). Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast Cancer Research and Treatment. 207(1). 33–48. 2 indexed citations

Nakayama, Izuma, Kazuo Kobayashi, Naoki Shibata, et al.. (2024). Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study. Biological and Pharmaceutical Bulletin. 47(2). 411–416. 1 indexed citations

Ozaki, Yukinori, Jun Masuda, Lina Inagaki, et al.. (2022). Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study. BMC Cancer. 22(1). 36–36. 4 indexed citations

Shimomura, Akihiko, Toshimi Takano, Shunji Takahashi, et al.. (2022). Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2‐Positive or HER2‐Low Metastatic/Unresectable Breast Cancer. Clinical Pharmacology & Therapeutics. 113(1). 160–169. 11 indexed citations

Jérusalem, Guy, Yeon Hee Park, Sara A. Hurvitz, et al.. (2022). Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer Discovery. 12(12). 2754–2762. 60 indexed citations

Yamashiro, Hiroyasu, Hiroji Iwata, Norikazu Masuda, et al.. (2020). Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. Breast Cancer. 27(4). 631–641. 5 indexed citations

Yamashita, Toshinari, Norikazu Masuda, Shigehira Saji, et al.. (2020). Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials. 21(1). 391–391. 10 indexed citations

Saitoh, Satoshi, Fumitaka Suzuki, Keiichi Kinowaki, et al.. (2020). Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography. Clinical Journal of Gastroenterology. 13(6). 1225–1232. 3 indexed citations

10.

Iwasa, Tsutomu, Junji Tsurutani, Satomi Watanabe, et al.. (2019). Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer. BMC Cancer. 19(1). 962–962. 2 indexed citations

11.

Takahashi, Momoko, Yukinori Ozaki, Jun Masuda, et al.. (2019). Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. BMC Cancer. 19(1). 980–980. 45 indexed citations

12.

Kuwayama, Takashi, Seigo Nakamura, Naoki Hayashi, et al.. (2018). Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2− Early-stage Breast Cancer. Clinical Breast Cancer. 18(6). 474–480. 22 indexed citations

13.

Hayashida, Tetsu, Aiko Nagayama, Tomoko Seki, et al.. (2018). Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. The Oncologist. 24(6). e347–e357. 31 indexed citations

14.

Masuda, Norikazu, Masakazu Toi, Naomi Yamamoto, et al.. (2018). Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial. Breast Cancer. 25(4). 407–415. 13 indexed citations

15.

Akamatsu, Hiroaki, Hideyuki Harada, Shoji Tokunaga, et al.. (2018). A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non–small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L). Clinical Lung Cancer. 20(1). e25–e27. 18 indexed citations

16.

Inoshita, Naoko, Yuji Miura, Ryosuke Oki, et al.. (2018). The loss of BAP1 protein expression predicts poor prognosis in patients with nonmetastatic clear cell renal cell carcinoma with inferior vena cava tumor thrombosis. Urologic Oncology Seminars and Original Investigations. 36(8). 365.e9–365.e14. 7 indexed citations

17.

Watanabe, Junichiro, Yoshinori Ito, Toshiaki Saeki, et al.. (2017). Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer. In Vivo. 31(3). 493–500. 18 indexed citations

18.

Takashima, Tsutomu, Hirofumi Mukai, Fumikata Hara, et al.. (2015). Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. The Lancet Oncology. 17(1). 90–98. 66 indexed citations

19.

Masuda, Norikazu, Kenji Higaki, Toshimi Takano, et al.. (2014). A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer. Cancer Chemotherapy and Pharmacology. 74(2). 229–238. 31 indexed citations

20.

Okano, Tetsuya, Tadashi Kondo, Kiyonaga Fujii, et al.. (2007). Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. Clinical Cancer Research. 13(3). 799–805. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact